SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and OptimizeRx (NASDAQ:OPRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Profitability
This table compares SOPHiA GENETICS and OptimizeRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -93.86% | -132.47% | -45.97% |
| OptimizeRx | 4.66% | 9.44% | 7.11% |
Earnings & Valuation
This table compares SOPHiA GENETICS and OptimizeRx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $77.27 million | 8.76 | -$79.00 million | ($1.15) | -7.02 |
| OptimizeRx | $109.43 million | 1.48 | $5.13 million | $0.23 | 37.26 |
OptimizeRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for SOPHiA GENETICS and OptimizeRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| OptimizeRx | 1 | 2 | 6 | 0 | 2.56 |
SOPHiA GENETICS presently has a consensus price target of $10.00, suggesting a potential upside of 23.92%. OptimizeRx has a consensus price target of $11.57, suggesting a potential upside of 35.02%. Given OptimizeRx’s stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than SOPHiA GENETICS.
Volatility and Risk
SOPHiA GENETICS has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Summary
OptimizeRx beats SOPHiA GENETICS on 13 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About OptimizeRx
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
